10-Q: Serina Therapeutics Reports Q2 Loss, Going Concern

Serina Therapeutics, a clinical-stage biotech, reported a significant net loss in Q2 2025, alongside a going concern warning, despite active capital raising and pipeline advancement.

Summary

• Serina Therapeutics reported a net loss of $6.5 million for the three months ended June 30, 2025, and $11.3 million for the six months ended June 30, 2025.
• The company's cash and cash equivalents increased to $6.0 million as of June 30, 2025, from $3.7 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $8.1 million, an improvement from $9.6 million in the prior year period.
• Total operating expenses significantly increased to $5.7 million for Q2 2025 and $11.6 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative costs.
• The accumulated deficit reached $55.6 million as of June 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern, as current cash is not expected to fund operations for the next 12 months.
• The company successfully raised $4.9 million in net proceeds from a private placement of Series A Convertible Preferred Stock in April 2025 and $0.6 million from an At-the-Market (ATM) offering by June 30, 2025.
• Material weaknesses in internal control over financial reporting were identified, with remediation efforts underway.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant net losses, a stated going concern risk, and identified material weaknesses in internal controls. While the company has successfully raised capital and is progressing its pipeline, these positive developments are overshadowed by the fundamental financial instability and operational control issues.

Positives

• Cash and cash equivalents increased to $6,041 thousand as of June 30, 2025, from $3,672 thousand at December 31, 2024.
• Net cash used in operating activities decreased to $8,072 thousand for the six months ended June 30, 2025, compared to $9,586 thousand for the same period in 2024, indicating a reduced cash burn rate.
• Successfully raised $4,940 thousand in net proceeds from the issuance of Series A Convertible Preferred Stock in April 2025.
• Generated $629 thousand in net proceeds from the At-the-Market (ATM) sales agreement by June 30, 2025.
• Advanced the lead product candidate, SER-252 (POZ-apomorphine), towards an Investigational New Drug (IND) application submission and planned Phase 1 clinical trial in 2025.
• Established a strategic partnership with Enable Injections, Inc. for the development and commercialization of SER-252.
• Increased investment in research and development, with expenses rising to $6,103 thousand for the six months ended June 30, 2025, reflecting active pipeline development.

Negatives

• Reported a net loss of $6,462 thousand for the three months ended June 30, 2025, a significant decline from a net income of $5,177 thousand in the prior year period.
• Incurred a net loss of $11,284 thousand for the six months ended June 30, 2025, compared to $9,838 thousand for the same period in 2024.
• Accumulated deficit grew to $55,579 thousand as of June 30, 2025.
• Management identified substantial doubt about the company's ability to continue as a going concern, as current cash is not expected to satisfy anticipated operating and other funding requirements for the next twelve months.
• Total operating expenses increased significantly to $11,553 thousand for the six months ended June 30, 2025, from $6,243 thousand in the prior year period.
• Material weaknesses in internal control over financial reporting were identified, indicating deficiencies in financial reporting processes and controls.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• The company will require significant additional financing to fund operations and product development, and there is no assurance that adequate financing will be available on favorable terms, if at all.
• Sales of additional equity securities, including through the At-the-Market (ATM) offering, could result in significant dilution to existing stockholders and cause the stock price to fall.
• The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, potentially leading to significant delays in clinical development and regulatory approval of product candidates.
• Reductions in staffing and resources at government agencies like the FDA, potentially due to government shutdowns or budget cuts, could result in delays in regulatory review timelines.
• The successful development and commercialization of product candidates are highly uncertain, and the company may never achieve regulatory approval or generate substantial product revenue.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SER-252 (POZ-apomorphine) and plans to initiate a Phase 1 clinical trial in advanced Parkinson's disease patients in 2025. It expects to incur substantial expenditures for product candidate development and will require additional financing. Research and development, general and administrative expenses, and capital expenditures are projected to increase as the company advances its pipeline, seeks regulatory approvals, and expands its operations and workforce.

Management Comments

• Management believes its cash and cash equivalents of $6.0 million as of June 30, 2025, are not expected to be sufficient to satisfy anticipated operating and other funding requirements for the twelve months from the issuance of these condensed consolidated interim financial statements.
• The company expects to largely rely on raising capital from equity investors and additional funding through its at-the-market offering (ATM) for funding operations.
• Management is implementing remedial measures to address identified material weaknesses in internal controls, including engaging financial operations employees and consultants, hiring professionals with technical expertise, leveraging third-party specialists, developing standardized templates, and implementing automation and integration improvements in financial IT systems.

Industry Context

Serina Therapeutics operates in the highly capital-intensive clinical-stage biotechnology sector, characterized by significant research and development expenditures, long development cycles, and stringent regulatory approval processes. The company's focus on neurological diseases and pain, utilizing its proprietary POZ drug delivery technology, positions it within a competitive landscape seeking to improve the efficacy and safety profiles of existing and novel drug candidates. The industry often sees companies at this stage relying heavily on external financing, such as equity offerings and licensing agreements, to fund operations through preclinical and clinical development, as product sales are typically years away.

Comparison to Industry Standards

• Specific comparable companies, projects, or results are not detailed in this filing to allow for a direct assessment against global benchmarks. The filing focuses on the company's internal financial performance and operational progress.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• On December 23, 2024, the company sold its wholly-owned subsidiary UniverXome to Juvenescence Limited for a nominal cash payment, with Juvenescence assuming approximately $11,300 thousand of secured debt (2022 Secured Note and 2023 Secured Note) owed by UniverXome to Juvenescence.
• Juvenescence exercised Post-Merger Warrants to purchase 377,865 shares of common stock for $5,000 thousand on June 6, 2024.
• On November 26, 2024, the company entered into an agreement with Juvenescence to issue 1,000,000 shares of common stock at $10.00 per share ($10,000 thousand aggregate) in two equal tranches, and Juvenescence surrendered its outstanding Post-Merger Warrants for Replacement Incentive Warrants. The second tranche of $5,000 thousand was received on January 31, 2025.

Stakeholder Impact

• Shareholders face potential significant dilution from ongoing and future equity offerings (e.g., ATM program, Series A Preferred Stock conversion) and the risk of stock price decline due to the going concern warning and increased losses.
• Employees may experience increased workload due to limited resources and internal control deficiencies, but also benefit from increased headcount and stock-based compensation.
• Patients with neurological diseases, particularly Parkinson's disease, could potentially benefit from the advancement of SER-252 and other product candidates if clinical trials are successful and regulatory approvals are obtained.
• Creditors, particularly Juvenescence, are impacted by the restructuring of debt and warrant agreements, and the company's ongoing liquidity challenges.

Next Steps

• Submit an Investigational New Drug (IND) application to the FDA for SER-252 (POZ-apomorphine).
• Initiate a Phase 1 clinical trial for SER-252 in advanced Parkinson's disease patients in 2025.
• Continue to advance other product candidates and preclinical programs to clinical trials.
• Further invest in the pipeline and seek regulatory approval for investigational medicines.
• Maintain, expand, protect, and defend the intellectual property portfolio.
• Secure facilities to support continued growth in research, development, and commercialization efforts.
• Increase headcount to support development efforts and expand the clinical development team.
• Continue implementation of remedial measures to address material weaknesses in internal controls, including hiring qualified personnel, leveraging consultants, developing standardized processes, and improving financial IT systems.

Key Dates

Recommendation

While Serina Therapeutics faces significant challenges, including substantial net losses, a stated going concern risk, and identified material weaknesses in internal controls, the company is actively pursuing strategies to address these issues. Recent capital raises, including a $4,940 thousand private placement and $629 thousand from an ATM offering, provide some near-term liquidity. Furthermore, the company is progressing its lead product candidate, SER-252, towards a Phase 1 clinical trial in 2025 and has established a strategic partnership, indicating ongoing R&D momentum. For existing investors, a 'hold' recommendation is warranted to observe the effectiveness of the remediation plan for internal controls and the progress of clinical development, particularly the IND submission and Phase 1 trial initiation. However, new investors should approach with extreme caution due to the high risk profile and liquidity concerns.

Keywords

Biotechnology, Clinical-stage, Drug Delivery, POZ Technology, Neurological Diseases, Parkinson's Disease, SEC Filing, 10-Q, SER-252, Capital Raise, Going Concern, Internal Controls